MC

452.3

-1.82%↓

SAF

290.9

+0.97%↑

SANES

8.005

+1.11%↑

BNP

81.77

+0.33%↑

CS.FR

42.16

+1.71%↑

MC

452.3

-1.82%↓

SAF

290.9

+0.97%↑

SANES

8.005

+1.11%↑

BNP

81.77

+0.33%↑

CS.FR

42.16

+1.71%↑

MC

452.3

-1.82%↓

SAF

290.9

+0.97%↑

SANES

8.005

+1.11%↑

BNP

81.77

+0.33%↑

CS.FR

42.16

+1.71%↑

MC

452.3

-1.82%↓

SAF

290.9

+0.97%↑

SANES

8.005

+1.11%↑

BNP

81.77

+0.33%↑

CS.FR

42.16

+1.71%↑

MC

452.3

-1.82%↓

SAF

290.9

+0.97%↑

SANES

8.005

+1.11%↑

BNP

81.77

+0.33%↑

CS.FR

42.16

+1.71%↑

Search

AB Science SA

Abrir

1.304 -0.46

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.262

Máximo

1.33

Indicadores-chave

By Trading Economics

Rendimento

-3.4M

Vendas

512K

Margem de lucro

-656.641

Funcionários

28

EBITDA

-1.9M

Dividendos

By Dow Jones

Próximos Ganhos

29 de set. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

84M

Abertura anterior

1.76

Fecho anterior

1.304

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

AB Science SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de ago. de 2025, 17:49 UTC

Grandes Movimentos do Mercado

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 de ago. de 2025, 17:18 UTC

Grandes Movimentos do Mercado

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 de ago. de 2025, 16:25 UTC

Ganhos

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 de ago. de 2025, 23:50 UTC

Conversa de Mercado

Nikkei May Rise as Yen Weakens -- Market Talk

11 de ago. de 2025, 23:42 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

11 de ago. de 2025, 23:42 UTC

Conversa de Mercado

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 de ago. de 2025, 23:36 UTC

Conversa de Mercado

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 de ago. de 2025, 23:32 UTC

Conversa de Mercado

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 de ago. de 2025, 23:02 UTC

Conversa de Mercado

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 de ago. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

11 de ago. de 2025, 20:37 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 de ago. de 2025, 20:37 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 de ago. de 2025, 20:37 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 de ago. de 2025, 20:22 UTC

Ganhos

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 de ago. de 2025, 20:22 UTC

Ganhos

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 de ago. de 2025, 20:22 UTC

Ganhos

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 de ago. de 2025, 20:22 UTC

Ganhos

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 de ago. de 2025, 20:22 UTC

Ganhos

Exodus Movement 2Q Rev $25.8M >EXOD

11 de ago. de 2025, 20:14 UTC

Conversa de Mercado

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 de ago. de 2025, 19:12 UTC

Conversa de Mercado

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 de ago. de 2025, 18:56 UTC

Conversa de Mercado

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 de ago. de 2025, 18:31 UTC

Conversa de Mercado

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 de ago. de 2025, 17:43 UTC

Conversa de Mercado

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 de ago. de 2025, 17:28 UTC

Conversa de Mercado

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 de ago. de 2025, 17:16 UTC

Conversa de Mercado

Commodity Longs Fall to 11-Month Low -- Market Talk

11 de ago. de 2025, 16:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 de ago. de 2025, 16:27 UTC

Aquisições, Fusões, Aquisições de Empresas

BBVA Says Sabadell Offer Remains in Effect

11 de ago. de 2025, 16:26 UTC

Aquisições, Fusões, Aquisições de Empresas

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 de ago. de 2025, 16:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Banco de Sabadell Announced TSB Sale on July 1

11 de ago. de 2025, 16:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Comparação entre Pares

Variação de preço

AB Science SA Previsão

Pontuação Técnica

By Trading Central

1.426 / 1.448Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bullish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.